A Phase II Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma.

Trial Profile

A Phase II Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 Aug 2015

At a glance

  • Drugs MK 2206 (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Acronyms AKTIL
  • Most Recent Events

    • 03 Jan 2014 Status changed from recruiting to discontinued, reported by ClinicalTrials.gov (NCT01466868).
    • 03 Jan 2014 Planned End Date changed from 1 May 2015 to 1 May 2014, reported by ClinicalTrials.gov (NCT01466868).
    • 11 Jan 2012 Actual initiation date changed from Dec 2011 to Nov 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top